All In Biotech

BLA 761055 · Regeneron Pharmaceuticals

Dupixent

Dupilumab · Injection · Interleukin-4 Receptor alpha Antagonist

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 28, 2017

Approved uses

20

Original approval plus efficacy supplements

Registered trials

220

59 Phase 3, 56 recruiting

FAERS reports

518,489

57,042 serious, 2,351 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2026.

DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous...

Mechanism: Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Inflammation driven by IL-4 and IL-13 is an important component in the pathogenesis of asthma, AD, CRSwNP, EoE, PN, COPD, CSU, BP, and AFRS. Multiple cell types that express IL-4Rα (e.g., mast cells, basophils, eosinophils, macrophages, lymphocytes, epithelial...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 22, 2026 Supplement 74 · Efficacy LetterLabel
  • Feb 23, 2026 Supplement 75 · Efficacy · priority review LabelLetter
  • Jun 18, 2025 Supplement 70 · Efficacy · priority review OrphanLabelLetter
  • Apr 17, 2025 Supplement 51 · Efficacy LabelLetter
  • Sep 27, 2024 Supplement 64 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Sep 12, 2024 Supplement 66 · Efficacy · priority review LabelLetter
  • Jan 25, 2024 Supplement 57 · Efficacy · priority review OrphanLabelLetter
  • Jan 12, 2024 Supplement 55 · Efficacy OrphanLabelLetter
  • Sep 28, 2022 Supplement 44 · Efficacy · priority review LabelLetter
  • Jun 7, 2022 Supplement 42 · Efficacy · priority review Breakthrough therapyLetterLabel
  • May 20, 2022 Supplement 40 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Oct 20, 2021 Supplement 31 · Efficacy LetterLabel
  • Jun 14, 2021 Supplement 16 · Efficacy LetterLabel
  • Jun 18, 2020 Supplement 17 · Efficacy LetterLabelReview
  • May 26, 2020 Supplement 20 · Efficacy · priority review LabelLetter
  • Jun 26, 2019 Supplement 14 · Efficacy · priority review LetterLabelReview
  • Mar 11, 2019 Supplement 12 · Efficacy · priority review Breakthrough therapyLabelLetterReview
  • Oct 19, 2018 Supplement 7 · Efficacy LabelLetterReview
  • Apr 10, 2018 Supplement 3 · Efficacy LabelLetter
  • Mar 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
1 products under this application
  • DUPIXENT · DUPILUMAB 150MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dupilumab" as an intervention, any sponsor and status, largest first.

All 220 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus65,143
  • dermatitis atopic48,270
  • product use in unapproved indication44,555
  • rash41,246
  • injection site pain40,378
  • drug ineffective32,504
  • dry skin28,839
  • eczema28,786
  • product dose omission issue25,576
  • condition aggravated21,742
  • arthralgia20,813
  • inappropriate schedule of product administration19,713

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20167
20171,107
20187,626
201914,912
202020,259
202140,308
202258,512
202366,771
202488,410
2025114,890
2026105,685

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 515 on PubMed

Sponsor: Regeneron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.